AbbVie has replaced Humira’s growth engine with fast-scaling Skyrizi and Rinvoq, but its premium valuation leaves returns dependent on sustained execution and pipeline delivery.
Overview
AbbVie is a global research-based biopharmaceutical company, separated from Abbott Laboratories in 2013, with franchises in immunology, neuroscience, oncology, aesthetics, and eye care/specialty products. Its commercial model sells proprietary therapies through wholesalers, specialty pharmacies, providers, governments, insurers, and PBMs; the United States is its dominant profit pool. The central investment story is the replacement of Humira with Skyrizi and Rinvoq: Q2 2026 revenues were $5.505 billion and $2.525 billion, growing 24.0% and 23.7% operationally, respectively, while Humira fell 36.1% to $756 million. Management targets combined Skyrizi/Rinvoq sales above $31 billion by 2027. Q2 revenue rose 10.2% reported to $16.990 billion, adjusted EPS was $3.65, and FY2026 revenue guidance increased to approximately $67.6 billion. **The post-Humira replacement strategy is working**, supported by neuroscience growth of 19.8% operationally and high margins. At $283.75, shares trade at 20.3x FY2026 and 17.4x FY2027 consensus adjusted EPS, with a 2.4–2.7% dividend yield. **Near-term catalysts include Skyrizi Crohn’s induction and acquired-pipeline milestones**, while price negotiation, competition, and leverage are key risks.